Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?

IF 4.1 2区医学 Q1 PHARMACOLOGY & PHARMACY

Expert opinion on investigational drugs Pub Date : 2025-09-01 Epub Date: 2025-08-27 DOI:10.1080/13543784.2025.2552847

Paola Marino, Antonella Argentiero, Davide Quaresmini, Elena Sapuppo, Dalila Tessitore, Giuliana Ciappina, Massimilano Berretta, Dario Giuffrida, Mariacarmela Santarpia, Nicola Silvestris

{"title":"Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?","authors":"Paola Marino, Antonella Argentiero, Davide Quaresmini, Elena Sapuppo, Dalila Tessitore, Giuliana Ciappina, Massimilano Berretta, Dario Giuffrida, Mariacarmela Santarpia, Nicola Silvestris","doi":"10.1080/13543784.2025.2552847","DOIUrl":null,"url":null,"abstract":"Introduction: Pancreatic neuroendocrine tumors (pNETs), a group of endocrine tumors that arise in the pancreas from the hormonal cells of the islets of Langerhans, are among the most common gastroenteropancreatic neuroendocrine tumors. The incidence of pNETs has increased in recent years to about 1.5 per 100,000 population and prognosis correlates with histologic grade.This review aims to provide an overview of the newly approved or currently developing drugs over the past five years that have shown a significant improvement in prognosis for patients affected by this rare disease.Areas covered: The literature search was conducted using PubMed, focusing on English-language publications from 2020 to 2025. Keywords included 'pancreatic neuroendocrine tumors,' 'new treatments,' 'targeted therapy,' and 'clinical trials.' Studies selected for inclusion comprised clinical trials, systematic reviews, and meta-analyses reporting data on treatment efficacy, safety, and patient quality of life.Expert opinion: Future research holds great potential, especially in improving personalized treatment predictions. Therefore, it is not easy to define a 'definitive endpoint' for research, as discoveries and technological innovations continue to evolve.","PeriodicalId":12313,"journal":{"name":"Expert opinion on investigational drugs","volume":" ","pages":"717-731"},"PeriodicalIF":4.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on investigational drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13543784.2025.2552847","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Pancreatic neuroendocrine tumors (pNETs), a group of endocrine tumors that arise in the pancreas from the hormonal cells of the islets of Langerhans, are among the most common gastroenteropancreatic neuroendocrine tumors. The incidence of pNETs has increased in recent years to about 1.5 per 100,000 population and prognosis correlates with histologic grade.This review aims to provide an overview of the newly approved or currently developing drugs over the past five years that have shown a significant improvement in prognosis for patients affected by this rare disease.

Areas covered: The literature search was conducted using PubMed, focusing on English-language publications from 2020 to 2025. Keywords included 'pancreatic neuroendocrine tumors,' 'new treatments,' 'targeted therapy,' and 'clinical trials.' Studies selected for inclusion comprised clinical trials, systematic reviews, and meta-analyses reporting data on treatment efficacy, safety, and patient quality of life.

Expert opinion: Future research holds great potential, especially in improving personalized treatment predictions. Therefore, it is not easy to define a 'definitive endpoint' for research, as discoveries and technological innovations continue to evolve.

查看原文本刊更多论文

胰腺神经内分泌肿瘤的研究药物：在过去的5年中我们看到了哪些临床进展？

胰腺神经内分泌肿瘤（Pancreatic neuroendocrine tumors, pNETs）是一组起源于胰腺朗格汉斯胰岛激素细胞的内分泌肿瘤，是最常见的胃肠胰腺神经内分泌肿瘤之一。近年来，pNETs的发病率已上升至每10万人中约1.5例，预后与组织学分级有关。本综述旨在概述过去五年来新批准或正在开发的药物，这些药物已显示出对这种罕见疾病患者预后的显着改善。涵盖领域：文献检索使用PubMed进行，重点是2020年至2025年的英语出版物。关键词包括“胰腺神经内分泌肿瘤”、“新疗法”、“靶向治疗”和“临床试验”。入选的研究包括临床试验、系统评价和荟萃分析，报告了治疗疗效、安全性和患者生活质量的数据。专家意见：未来的研究具有巨大的潜力，特别是在改善个性化治疗预测方面。因此，随着发现和技术创新的不断发展，为研究定义一个“最终终点”并不容易。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert opinion on investigational drugs 医学-药学

CiteScore

10.00

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development. The Editors welcome: Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies Drug Evaluations reviewing the clinical and pharmacological data on a particular drug Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.